Diaceutics (LON:DXRX) Posts Earnings Results

Key Points

• Diaceutics reported a quarterly earnings per share (EPS) of GBX 2.84, alongside a negative return on equity of 7.15% and net margin of 10.90%.
• The company's stock opened at GBX 156.20, with a market capitalization of £132.06 million and a price-to-earnings ratio of -7,732.67.
• Analysts have a consensus rating of "Buy" for Diaceutics, with an average target price of GBX 175, although Royal Bank of Canada recently lowered their price target to GBX 185.

Diaceutics (LON:DXRX - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported GBX (2.84) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Diaceutics had a negative return on equity of 7.15% and a negative net margin of 10.90%.

Diaceutics Price Performance

LON DXRX opened at GBX 156.20 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.85 and a quick ratio of 9.92. The stock's fifty day moving average price is GBX 137.39 and its 200 day moving average price is GBX 127.74. Diaceutics has a 1 year low of GBX 106 and a 1 year high of GBX 156.50. The company has a market cap of £132.06 million, a price-to-earnings ratio of -7,732.67 and a beta of 0.58.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on DXRX shares. Royal Bank Of Canada reduced their price target on Diaceutics from GBX 195 to GBX 185 and set an "outperform" rating on the stock in a research report on Thursday, July 10th. Canaccord Genuity Group reaffirmed a "buy" rating and set a GBX 180 price target on shares of Diaceutics in a research report on Tuesday, July 22nd. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, Diaceutics presently has a consensus rating of "Buy" and an average target price of GBX 175.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.